{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:55:07Z","timestamp":1771880107012,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T00:00:00Z","timestamp":1294185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11897-010-0046-0","type":"journal-article","created":{"date-parts":[[2011,1,3]],"date-time":"2011-01-03T22:23:06Z","timestamp":1294093386000},"page":"7-13","source":"Crossref","is-referenced-by-count":22,"title":["Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HF"],"prefix":"10.1007","volume":"8","author":[{"given":"Miriam S.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,5]]},"reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/CIRCULATIONAHA.109.192667","volume":"121","author":"D Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones D, Adams RJ, Brown TM, et al.: Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association. Circulation 2010;121:e46\u2013e215.","journal-title":"Circulation"},{"key":"46_CR2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0735-1097(01)01714-4","volume":"39","author":"WH Tang","year":"2002","unstructured":"Tang WH, Vagelos RH, Yee YG, et al.: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:70\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"46_CR3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardfail.2010.04.005","volume":"16","author":"Heart Failure Society of America","year":"2010","unstructured":"\u2022 Heart Failure Society of America. Executive summary: HFSA 2010 Comprehensive heart failure practice guideline. Journal of Cardiac Failure 2010;16:475\u2013539. This article presents quideline recommendations from the HFSA, including current recommended use of aldosterone blockade.","journal-title":"Journal of Cardiac Failure"},{"key":"46_CR4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"SA Hunt","year":"2009","unstructured":"\u2022 Hunt SA, Abraham WT, Chin MH, et al.: 2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1\u2013e90. This article presents guideline recommendations from the ACC and the AHA, including indications for use of aldosterone blocakde.","journal-title":"J Am Coll Cardiol"},{"key":"46_CR5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"46_CR6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"46_CR7","unstructured":"\u2022\u2022 Zannad F, McMurray JJ, Krum H, et al.: Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2010. This article presents the EMPHASIS-HF study, the latest randomized control trial for the use of aldosterone antagonists in NYHA class II patients with systolic heart failure."},{"key":"46_CR8","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","volume":"112","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Anavekar N, Skali H, et al.: Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005;112:3738\u201344.","journal-title":"Circulation"},{"key":"46_CR9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","volume":"56","author":"DG Kramer","year":"2010","unstructured":"\u2022 Kramer DG, Trikalinos TA, Kent DM, et al.: Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010;56:392\u2013406. This article highlights the effect of aldosterone antagonists on markers of left ventricular remodeling.","journal-title":"J Am Coll Cardiol"},{"key":"46_CR10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","volume":"30","author":"JA Ezekowitz","year":"2009","unstructured":"Ezekowitz JA, McAlister FA: Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469\u201377.","journal-title":"Eur Heart J"},{"key":"46_CR11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","volume":"3","author":"JE Udelson","year":"2010","unstructured":"Udelson JE, Feldman AM, Greenberg B, et al.: Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010;3:347\u201353.","journal-title":"Circ Heart Fail"},{"key":"46_CR12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","volume":"11","author":"A Boccanelli","year":"2009","unstructured":"Boccanelli A, Mureddu GF, Cacciatore G, et al.: Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail 2009;11:68\u201376.","journal-title":"Eur J Heart Fail"},{"key":"46_CR13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","volume":"106","author":"E Vizzardi","year":"2010","unstructured":"Vizzardi E, D\u2019Aloia A, Giubbini R, et al.: Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 2010;106:1292\u20136.","journal-title":"Am J Cardiol"},{"key":"46_CR14","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","volume":"112","author":"H Izawa","year":"2005","unstructured":"Izawa H, Murohara T, Nagata K, et al.: Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 2005;112:2940\u20135.","journal-title":"Circulation"},{"key":"46_CR15","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700\u20136.","journal-title":"Circulation"},{"key":"46_CR16","unstructured":"Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT). 2010. (Accessed December 6, 2010, at http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00094302?term=topcat&rank=1 .)"},{"key":"46_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1254\/jphs.08R02CR","volume":"108","author":"H Kiyomoto","year":"2008","unstructured":"Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A: Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci 2008;108:399\u2013405.","journal-title":"J Pharmacol Sci"},{"key":"46_CR18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543\u201351.","journal-title":"N Engl J Med"},{"key":"46_CR19","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","volume":"289","author":"DN Juurlink","year":"2003","unstructured":"Juurlink DN, Mamdani M, Kopp A, et al.: Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652\u20138.","journal-title":"JAMA"},{"key":"46_CR20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","volume":"10","author":"M Svensson","year":"2004","unstructured":"Svensson M, Gustafsson F, Galatius S, et al.: How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297\u2013303.","journal-title":"J Card Fail"},{"key":"46_CR21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"JW Funder","year":"2008","unstructured":"Funder JW: Reconsidering the roles of the mineralocorticoid receptor. Hypertension 2008;53:286\u201390.","journal-title":"Hypertension"},{"key":"46_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ahj.2009.11.022","volume":"159","author":"NM Albert","year":"2010","unstructured":"\u2022 Albert NM, Fonarow GC, Yancy CW, et al.: Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Am Heart J 2010;159:238\u201344. This is a study of the real-life utilization of guideline-recommended therapies (medical and device) in patients with systolic heart failure.","journal-title":"Am Heart J"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-010-0046-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-010-0046-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-010-0046-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T10:37:33Z","timestamp":1559903853000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-010-0046-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s11897-010-0046-0","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,5]]}}}